Robert G Gish Consultants

05/28/2026

Great catching up with colleagues and friends over dinner while attending in beautiful Barcelona 🇪🇸🍷 Always inspiring to share ideas, collaborations, and conversations outside the conference halls!

05/27/2026

I am excited to be attending the European Association for the Study of the Liver (EASL) Congress this week in beautiful Barcelona, Spain 🇪🇸✨ Looking forward to connecting with colleagues from around the world, discussing the latest advances in hepatology, and sharing ideas to improve liver disease care globally

The energy and innovation at continue to inspire collaboration and progress in viral hepatitis, fatty liver disease, liver cancer, and beyond 🩺🌍 Safe travels to everyone attending — see you in Barcelona!

EASL - The Home of Hepatology

05/12/2026

Interested in attending the Asia-Pacific Workshop on HBVCURE in Seoul?
Message me for a registration discount! Limited quantities, so act fast!

May is Hepatitis Awareness Month! ❤️

Today, we have powerful tools at our disposal: effective vaccines, long-term antiviral therapies, and even a cure for Hepatitis C.

For Hepatitis B specifically, a functional cure remains the next frontier. As a rapidly evolving field, scientific exchange is crucial to critically discuss the latest data, define barriers, and stimulate new concepts.

We invite you to join us for a scientific exchange forum designed to address precisely this need.

What participants can expect from the 𝟭𝘀𝘁 𝗔𝘀𝗶𝗮-𝗣𝗮𝗰𝗶𝗳𝗶𝗰 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽 𝗼𝗻 𝗛𝗕𝗩 𝗖𝘂𝗿𝗲:
• The latest clinical and translational HBV cure research from across the Asia-Pacific region
• In-depth discussion on key barriers and the path toward HBV functional cure
• Opportunities to build lasting research collaborations and networks across the region
• A shared scientific agenda bridging academia, clinical practice, biotech, and pharma

If you work in HBV research, clinical hepatology, or drug development, join us in Seoul!

🔗 Register here: https://amededu.co/3OVJGT1

05/11/2026

New publication! 📖

Our latest article highlights the importance of recognizing and actively treating itch symptoms in patients with liver disease. Too often, pruritus is underestimated — but for many patients, it significantly impacts quality of life and sleep.

I am now asking every patient:
➡️ “How much itching do you have?”
➡️ “How many hours per day?”
➡️ “Rate your itching scale of 0–10?”
➡️ “Does it interfere with sleep?”

And I’m treating all itch symptoms using my itch management sheet, available at robertgish.com

It’s time to make symptom assessment part of routine liver care. Early recognition and treatment matter.

Read the article here:
https://onlinelibrary.wiley.com/doi/10.1002/lci2.70044

Background and Aims Pruritus is a debilitating, under-prioritized symptom of primary biliary cholangitis (PBC). This study assessed its impact on healthcare resource utilization (HCRU) and costs in ...

05/05/2026

The World Health Organization has released its Global Hepatitis Report 2026—and the message is clear: progress is real, but we are still off track to meet 2030 elimination goals.

📊 Key takeaways:
• Viral hepatitis still causes ~1.3 million deaths annually worldwide
• ~240 million people are living with chronic hepatitis B and ~47 million with hepatitis C
• New hepatitis B infections are down 32%, and hepatitis C deaths have dropped 12% since 2015
• Yet treatment gaps remain stark—

The Global hepatitis report 2026 warns that viral hepatitis remains a leading global health problem, despite the availability of a highly effective hepatitis B vaccine since the 1990s, effective antiviral treatments for chronic hepatitis B infection and, since 2015, a 12-week antiviral treatment for...

04/29/2026

New data on hepatitis D virus (HDV) prevalence in the U.S. continues to refine our understanding of this underdiagnosed infection. A recent study in Clinical Infectious Diseases journal reports HDV seroprevalence of ~1.26% among HBsAg+ individuals in NHANES samples —highlighting both progress in measurement and ongoing gaps in detection.

I believe that the true prevalence of HDV infection in the US is probably in the 2–3% range of HBsAg+ patients, with total PCR+ patients in the US likely fewer than 70,000

As testing strategies evolve, improving awareness and access to HDV screening remains critical to identifying patients earlier and improving outcomes

🔗 Read the article: https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciag274/8662345?utm_source=authortollfreelink&utm_campaign=cid&utm_medium=email

Abstract. To validate the accuracy of previously published US seroprevalence estimates for hepatitis D virus (HDV) antibody, we retested National Health an

04/28/2026

I am excited to be presenting at an upcoming Medscape LIVE CME program during Digestive Disease Week in Chicago this Saturday, May 3!

Join me and an outstanding panel of colleagues as we dive into practical, case-based strategies to improve care for patients with primary biliary cholangitis (PBC).

💭 PBC isn’t just about numbers—it’s about quality of life
🔬 Understand when to escalate beyond first-line therapy
📌 Identify high-risk patients earlier
🧩 Integrate emerging therapies to improve real-world outcomes

🗓 Don’t miss this opportunity to stay current, earn CME credit, and engage in meaningful discussion with peers

✨ Access 🔗https://mdsc.pe/4szBBSe

Looking forward to seeing you there!

04/27/2026

It was great to see such an inspiring group of experts coming together at in Istanbul last week!

I was joined by fellow leaders in liver disease to share insights, advance collaboration, and push the field forward. Exciting progress ahead! 🌍✨

04/24/2026

🌍 Share your research at !

The 9th Conference on Liver Disease in Africa (COLDA 2026) is now accepting abstracts—and this is your opportunity to contribute to advancing liver health across the globe.

We’re inviting submissions on a wide range of topics, including:
🔬 Hepatitis B (HBV)
🧬 Hepatitis C (HCV)
🧪 Diagnostics & innovative tools
🤝 Co-infections and more

👉 View the program and submit your abstract here: https://bit.ly/4imGRVX

🗓 Abstract deadline: June 19, 2026

Join leading experts, showcase your work, and be part of the conversation driving progress in liver disease research and care.

04/17/2026

An important article to read:
"Shared principles within HBV guidelines: aligning clinical approach with differentiated care for global elimination"

➡️ https://www.thelancet.com/journals/langas/article/PIIS2468-1253(26)00050-6/abstract

I really like the word "Yes"

✔️ Yes to treating all
✔️ Treat all HBV DNA+
✔️ If HBV DNA PCR is not available, treat all HBsAg+

This is the kind of mindset shift that can truly move the needle toward elimination

The next step is clear - Let's work on treatment access!

Global hepatitis B treatment efforts are at a turning point. Major treatment guidelines have been updated in the past few years, including from the Chinese Society of Hepatology and Chinese Society of Infectious Diseases in 2022,1 WHO in 2024,2 and the European Association for the Study of the Liver...